BioCryst Pharmaceuticals (BCRX)
(Delayed Data from NSDQ)
$7.52 USD
-0.33 (-4.20%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $7.51 -0.01 (-0.13%) 7:58 PM ET
1-Strong Buy of 5 1
F Value C Growth F Momentum F VGM
Brokerage Reports
0 items in cart
BioCryst Pharmaceuticals, Inc. [BCRX]
Reports for Purchase
Showing records 101 - 120 ( 176 total )
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
4Q13 In-line; OPuS-1 Data in June Will Likely Create Meaningful Catalyst
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Peramivir PDUFA Set for Dec 23; We Expect Approval and BARDA Award
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Initiate BUY at $18 PT
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
We are under review due to the departure from the firm of analyst
Provider: RODMAN & RENSHAW, CO.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
We are under review due to the departure from the firm of analyst
Provider: RODMAN & RENSHAW, CO.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Review of Statistical Analysis Supports Increased Confidence in Safety Profile for BCX-4208
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Review of Statistical Analysis Supports Increased Confidence in Safety Profile for BCX-4208
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Data at ACR Provide a More Complete Picture of Phase 2b Findings for BCX-4208
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Data at ACR Provide a More Complete Picture of Phase 2b Findings for BCX-4208
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
An Underappreciated Name in Gout & Influenza Continues to Execute - Late Breaker at ACR
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
An Underappreciated Name in Gout & Influenza Continues to Execute - Late Breaker at ACR
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.